Decision to list medical devices in the endomechanical and electrosurgical category supplied by Device Technologies Australia Pty Ltd
We are pleased to announce the approval of a listing agreement for medical devices with Device Technologies Australia Pty Ltd for products in the endomechanical and electrosurgical category of medical devices.
What we are doing
We are pleased to announce the approval of a listing agreement for medical devices with Device Technologies Australia Pty Ltd (“Device Technologies Australia”) for products in the endomechanical and electrosurgical category of medical devices.
Any changes to the original proposal?
No changes have been made to the agreement as a result of consultation.
Who we think will be most interested
- Clinical and non-clinical DHB staff:
- Clinical/Biomedical Engineers
- Perioperative staff
- Sterile services staff
- Outpatient procedure clinic staff
- Procurement and supply chain personnel
- Suppliers and Wholesalers
Detail about this decision
The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
After completing the RFP evaluation processes and consulting on the proposed agreement with Device Technologies Australia to list their range of Endomechanical and Electrosurgical Products. PHARMAC has decided to list the medical devices in Part lll of Section H of the Pharmaceutical Schedule from 1 August 2019.
DHBs that purchase this category of medical devices from Device Technologies Australia must do so under the terms and conditions, and the prices included in the Agreement from the listing date. DHBs can continue to choose which Endomechanical and Electrosurgical Products they purchase.
The Agreement includes terms and conditions for training and education to be provided by Device Technologies Australia, on the appropriate use of their products, which is to be provided at times as agreed with individual DHBs.
Our response to what you told us
We appreciate the time people took to respond to this consultation.
All consultation responses received by 26 June 2019 were considered in their entirety in making the decision to list these products.
A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
Feedback received that no technical or resource impacts are expected as a result of the proposal.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.